Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study

Abstract Background Pulmonary exacerbations (PEx) are a major driver of morbidity and mortality in cystic fibrosis and reducing their frequency by extending the time between them is an important therapeutic goal. Although treatment decisions for exacerbations are often made based on dynamic changes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Julia C. Espel, Hannah L. Palac, Joanne F. Cullina, Alexandria P. Clarke, Susanna A. McColley, Michelle H. Prickett, Manu Jain
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2017-11-01
Schriftenreihe:BMC Pulmonary Medicine
Schlagworte:
Antibiotics
Bronchiectasis
Cystic fibrosis
Exacerbation
Outcomes Pseudomonas aeruginosa
Online Zugang:http://link.springer.com/article/10.1186/s12890-017-0503-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge